eISSN 2329-0358


Get your full text copy in PDF

Ezetimibe in sirolimus-associated hyperlipidemia: To add or not to add to statins?

Mariusz Niemczyk, Leszek Paczek

Ann Transplant 2011; 16(3): 132-134

ID: 882006

Background:    Hyperlipidemia is a universal adverse effect of proliferation signal inhibitors (PSI). We report our experience with ezetimibe/statin combined therapy in a case of a kidney transplant recipient receiving sirolimus (SRL)-based immunosuppression. We also present our doubts concerning the need for ezetimibe in kidney transplant recipients on PSI-based immunosuppression.
    Case Report:    Results. In the reported patient, ezetimibe/statin combination therapy successfully decreased cholesterol level.
    Conclusions:    Combined therapy with ezetimibe and statin seems to be effective and safe in transplant recipients with SRL-associated hyperlipidemia. However, well-designed clinical trials should be performed to evaluate if there is an impact of such treatment on the frequency of cardiovascular events and patient survival.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree